All In Biotech

Drug Trial Radar · NCT05276570

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

A Phase 1/2a Study Evaluating the Effects of ARO-RAGE Inhalation Solution in Healthy Subjects and Patients With Inflammatory Lung Disease

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

127

Actual

Start

Jun 29, 2022

Primary completion

Apr 16, 2025

Study completion Apr 16, 2025

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ARO-RAGE in normal healthy volunteers (NHVs) and in participants with inflammatory lung disease (asthma). In Part 1 of the study, NHVs will receive a single dose of ARO-RAGE or placebo. In Part 2 of the study, adult participants with asthma will receive 2 doses of ARO-RAGE or placebo. Additional NHVs may be randomized to receive 1 or 2 doses of ARO-RAGE or placebo at Sponsor discretion. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.

Conditions

  • Asthma

Interventions

  • ARO-RAGEDrug

    single or multiple doses of ARO-RAGE by inhalation of nebulized solution

  • PlaceboDrug

    calculated volume to match active treatment by inhalation of nebulized solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug through the end of study (EOS; up to 113 days)

Locations

8 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site 1

    Nedlands, Washington, Australia

  • Research Site 1

    Auckland, New Zealand

  • Research Site 2

    Auckland, New Zealand

  • Research Site 3

    Auckland, New Zealand

  • Research Site 2

    Krakow, Poland

  • Research Site 3

    Oświęcim, Poland

  • Research Site 1

    Barcelona, Spain

  • Research Site 1

    Bangkok Noi, Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.